

---

***Eurofins BioPharma  
Product Testing Denmark  
Holding A/S***

Smedeskovvej 38, DK-8464 Galten

**Annual Report for 1 January - 31  
December 2023**

---

CVR No 37 06 44 08

The Annual Report was  
presented and adopted at  
the Annual General  
Meeting of the Company on  
24<sup>th</sup> May 2024



Svend Aage Linde  
Chairman

# Contents

	<u>Page</u>
<b>Management's Statement and Auditor's Report</b>	
Management's Statement	1
Independent Auditor's Report	2
<b>Company Information</b>	
Company Information	5
Management Commentary	6
<b>Financial Statements</b>	
Income Statement 1 January - 31 December 2023	7
Balance Sheet 31 December 2023	8
Equity Statement 31 December 2023	10
Notes to the Financial Statements	11
Accounting Policies	13

## Management's Statement

The Executive Board and Board of Directors have today considered and adopted the Annual Report of Eurofins BioPharma Product Testing Denmark Holding A/S for the financial year 1 January - 31 December 2023.

The Annual Report is prepared in accordance with the Danish Financial Statements Act.

In our opinion the Financial Statements give a true and fair view of the financial position at 31 December 2023 of the Company and of the results of the Company operations for 2023.

In our opinion, Management's Review includes a true and fair account of the matters addressed in the Review.

We recommend that the Annual Report be adopted at the Annual General Meeting.


Galten, 24<sup>th</sup> May 2024

### Executive Board

  
Stefania Pcolova

### Board of Directors

  
Svend Aage Linde  
Chairman

  
Marco Antonio Giuseppe Baeli

  
Jan Rando

# **Independent Auditor's Report**

**To the Shareholder of Eurofins BioPharma Product Testing Denmark Holding A/S**

## **Opinion**

We have audited the financial statements of Eurofins BioPharma Product Testing Denmark Holding A/S for the financial year 01.01.2023 -31.12.2023, which comprise the income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Entity's financial position at 31.12.2023 and of the results of its operations for the financial year 01.01.2023 - 31.12.2023 in accordance with the Danish Financial Statements Act.

## **Basis for Opinion**

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of this auditor's report. We are independent of the Entity in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## **Management's Responsibilities for the Financial Statements**

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Entity's ability to continue as a going concern, for disclosing, as applicable, matters related to going concern, and for using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

## **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

## Independent Auditor's Report

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements, and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures in the notes, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

# Independent Auditor's Report

## Statement on the management commentary

Management is responsible for the management commentary.

Our opinion on the financial statements does not cover the management commentary, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the management commentary provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the management commentary is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the management commentary.

Aarhus, 24<sup>th</sup> May 2024

**Deloitte**

Statsautoriseret Revisionspartnerselskab

CVR-nr. 33 96 35 56



Henrik Vedel

Statsautoriseret revisor

*State Authorised Public Accountant*

MNE-nr.: mne10052

## **Company Information**

### **The Company**

Eurofins BioPharma Product Testing Denmark Holding A/S  
Smedeskovvej 38  
DK-8464 Galten

CVR No: 37 06 44 08

Financial period: 1 January - 31 December

Municipality of reg. office: Skanderborg

### **Board of Directors**

Svend Aage Linde, Chairman  
Marco Antonio Giuseppe Baeli  
Jan Rando

### **Executive Board**

Stefania Pcolova

### **Auditors**

Deloitte  
Statsautoriseret Revisionspartnerselskab  
Værkmestergade 2, 18  
DK-8000 Aarhus C

## **Management Commentary**

### **Main activity**

The activities of the Company are to manage investments in subsidiaries.

### **Development in the year**

The income statement of the Company for 2023 shows a profit of DKK 3.606.153, which is considered satisfactory.

### **Subsequent events**

No events materially affecting the assessment of the Annual Report have occurred after the balance sheet date.



## Income Statement 1 January - 31 December

	Note	2023	2022
		DKK	DKK
<b>Gross profit</b> <i>Gross profit</i>		-92.640	-87.649
Write-down of investments in subsidiaries		-3.000.000	0
<b>Profit/loss before financial income and expenses</b>		<b>-3.092.640</b>	<b>-87.649</b>
Income from investments in subsidiaries		9.500.000	10.000.000
Financial income	2	99.693	11.502
Financial expenses	3	-3.717.113	-2.615.739
<b>Profit/loss before tax</b>		<b>2.789.940</b>	<b>7.308.114</b>
Tax on profit/loss for the year		816.213	592.215
<b>Net profit/loss for the year</b>		<b>3.606.153</b>	<b>7.900.329</b>

### Distribution of profit

	2023	2022
	DKK	DKK
<b>Proposed distribution of profit</b>		
Proposed dividend for the year	1.800.000	5.300.000
Retained earnings	1.806.153	2.600.329
	<b>3.606.153</b>	<b>7.900.329</b>

## Balance Sheet 31 December

### Assets

	Note	<u>2023</u> DKK	<u>2022</u> DKK
Investments in subsidiaries		<u>58.000.000</u>	<u>58.000.000</u>
<b>Fixed assets</b>		<b><u>58.000.000</u></b>	<b><u>58.000.000</u></b>
Receivables from group enterprises	4	7.730.643	6.526.044
Receivables from group enterprises from tax		816.213	592.215
<b>Receivables</b>		<b><u>8.546.856</u></b>	<b><u>7.118.259</u></b>
<b>Current assets</b>		<b><u>8.546.856</u></b>	<b><u>7.118.259</u></b>
<b>Assets</b>		<b><u>66.546.856</u></b>	<b><u>65.118.259</u></b>

## Balance Sheet 31 December

### Liabilities and equity

	Note	2023 DKK	2022 DKK
Share capital		500.000	500.000
Retained earnings		17.807.893	13.001.740
Proposed dividend for the year		1.800.000	5.300.000
<b>Equity</b>		<b>20.107.893</b>	<b>18.801.740</b>
Payables to group enterprises		45.431.346	45.431.346
<b>Long term payables</b>	5	<b>45.431.346</b>	<b>45.431.346</b>
Payables to group enterprises		990.741	870.772
Other payables		16.875	14.400
<b>Short-term debt</b>		<b>1.007.616</b>	<b>885.172</b>
<b>Debt</b>		<b>46.438.962</b>	<b>46.316.519</b>
<b>Liabilities and equity</b>		<b>66.546.856</b>	<b>65.118.259</b>
Subsequent events	1		
Contingent liabilities	6		
Consolidated Financial Statements	7		

## Equity Statement 31 December 2023

### Equity

	Share capital	Retained earnings	Proposed dividend for the year	Total
	DKK	DKK	DKK	DKK
Equity at 1 January 2023	500.000	13.001.740	5.300.000	18.801.740
Ordinary dividend paid	0	0	-5.300.000	-5.300.000
Capital contribution	0	3.000.000	0	3.000.000
Net profit/loss for the year	0	1.806.154	1.800.000	3.606.154
<b>Equity at 31 December 2023</b>	<b>500.000</b>	<b>17.807.893</b>	<b>1.800.000</b>	<b>20.107.893</b>

## Notes to the Financial Statements

### 1 Subsequent events

No events materially affecting the assessment of the Annual Report have occurred after the Balance sheet date.

	<u>2023</u>	<u>2022</u>
	DKK	DKK
<b>2 Financial income</b>		
Other financial income	99.693	11.502
	<u><b>99.693</b></u>	<u><b>11.502</b></u>

	<u>2023</u>	<u>2022</u>
	DKK	DKK
<b>3 Financial expenses</b>		
Interest paid to group enterprises	3.717.113	2.615.739
	<u><b>3.717.113</b></u>	<u><b>2.615.739</b></u>

### 4 Receivables from group enterprises

The Company is a part of cash pool with Eurofins NSC Denmark A/S. Receivable from this cash pool is included in receivables from group enterprises and amounts to 7,7 MDKK (2022: 6,5 MDKK).

## Notes to the Financial Statements

### 5 Long-term debt

Payments due within 1 year are recognized in short-term debt. Other debt is recognized in long-term debt.

The debt falls due for payment as specified below:

	2023	2022
	DKK	DKK
<b>Payables to group enterprises</b>		
Between 1 and 5 years	45.431.346	45.431.346
Other short-term debt to group enterprises	990.741	870.772
	<b>46.422.087</b>	<b>46.302.119</b>

### 6 Contingent liabilities

The Company is included in the national joint taxation with Eurofins NSC Denmark A/S as management company and is jointly and severally liable together with the other jointly taxed companies for the Group's jointly taxed income. The Company is jointly and severally liable together with the other jointly taxed companies for any obligation to withhold tax on interests, royalties and dividends.

### 7 Consolidated Financial Statements

The Group is included in the Group Annual Report of the Parent Company

Name	Place of registered office
Eurofins Scientific S.E.	23, Val Fleuri, L-1526, Luxembourg

## **Accounting Policies**

### **Basis of Preparation**

The Annual Report of Eurofins BioPharma Product Testing Denmark Holding A/S for 2023 has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises with addition of certain provisions for reporting class C.

The accounting policies applied remain unchanged from last year.

Financial Statements for 2023 are presented in DKK.

### **Recognition and measurement**

Revenues are recognised in the income statement as earned. Furthermore, value adjustments of financial assets and liabilities measured at fair value or amortised cost are recognised. Moreover, all expenses incurred to achieve the earnings for the year are recognised in the income statement, including depreciation, amortisation, impairment losses and provisions as well as reversals due to changed accounting estimates of amounts that have previously been recognised in the income statement.

Assets are recognised in the balance sheet when it is probable that future economic benefits attributable to the asset will flow to the Company, and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when it is probable that future economic benefits will flow out of the Company, and the value of the liability can be measured reliably.

Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described for each item below.

## **Income Statement**

### **Gross profit/loss**

With reference to section 32 of the Danish Financial Statements Act, revenue has not been disclosed in the Annual Report.

### **Other external expenses**

Other external expenses comprise indirect production costs and expenses for premises, sales and distribution as well as office expenses, etc.

### **Income from investments in subsidiaries**

Dividends from subsidiaries are recognised as income in the income statement when adopted at the General Meeting of the subsidiary. However, dividends relating to earnings in the subsidiary before it was acquired by the Parent Company are set off against the cost of the subsidiary.

## **Accounting Policies**

### **Financial income and expenses**

Financial income and expenses are recognised in the income statement at the amounts relating to the financial year.

### **Tax on profit/loss for the year**

Tax for the year consists of current tax for the year and changes in deferred tax for the year. The tax attributable to the profit for the year is recognised in the income statement, whereas the tax attributable to equity transactions is recognised directly in equity.

The Company is jointly taxed with wholly owned Danish and foreign subsidiaries. The tax effect of the joint taxation is allocated to enterprises in proportion to their taxable incomes.

## **Balance Sheet**

### **Investments in subsidiaries**

Investments in subsidiaries are measured at cost. Where cost exceeds the recoverable amount, write-down is made to this lower value.

### **Receivables**

Receivables are recognised in the balance sheet at amortised cost, which substantially corresponds to nominal value. Provisions for estimated bad debts are made.

### **Deferred tax assets and liabilities**

Deferred income tax is measured using the balance sheet liability method in respect of temporary differences arising between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes on the basis of the intended use of the asset and settlement of the liability, respectively.

Deferred tax assets are measured at the value at which the asset is expected to be realised, either by elimination in tax on future earnings or by set-off against deferred tax liabilities within the same legal tax entity.

Deferred tax is measured on the basis of the tax rules and tax rates that will be effective under the legislation at the balance sheet date when the deferred tax is expected to crystallise as current tax. Any changes in deferred tax due to changes to tax rates are recognised in the income statement or in equity if the deferred tax relates to items recognised in equity.

### **Financial debts**

Debts are measured at amortised cost, substantially corresponding to nominal value.